MMJ International Holdings Announces MOU for Manufacturing of THC-CBD Derived Drugs

Share Article

Under the terms of the agreement, MMJ International Holdings will develop the active pharmaceutical ingredient (API) for its drug product MMJ 001 as a liquid-filled gel capsule. ThermoFisher Scientific will be supporting MMJ with the FDA, DEA required development protocols applying collaborative, scalable and science-based approaches.

“We firmly believe that our MMJ natural whole plant derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases,” said Duane Boise, CEO of MMJ.

MMJ International Holdings has announced an agreement for manufacturing of its oral drug product for the treatment of multiple sclerosis (MS) and Huntington’s disease (HD) with Thermo Fisher Scientific.

Under the terms of the agreement, MMJ International Holdings will develop the active pharmaceutical ingredient (API) for drug product MMJ 001 as a liquid-filled gel capsule. MMJ-001 is derived from the marijuana plant containing THC and CBD as a natural whole plant extract.

“As MMJ International Holdings continues to advance to its clinical trials, ThermoFisher Scientific will be supporting MMJ with the FDA, DEA required development API for MMJ's specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of research & development.. “Patients will be expected to benefit from cGMP-quality therapies in an accessible and efficient format.”

This manufacturing agreement enables the development and future commercialization of MMJ’s novel THC and CBD cannabinoid-based medicine for therapeutic applications across a broad range of diseases once FDA approved. MMJ International Holdings has been at the forefront of THC, CBD based drug research for the treatment of serious diseases, including Multiple Sclerosis (MS) and Huntington’s disease (HD).

“We firmly believe that our MMJ natural whole plant derived molecules with a unique combination of pharmacological properties will be FDA approved as a safe and effective prescription drug that can be of great benefit in treating patients with MS and HD diseases,” said Duane Boise, CEO of MMJ International Holdings. “This agreement with Thermo Fisher Scientific will help us succeed with our company mission to service the unmet needs of patients suffering from these chronic diseases.”

This joint development program will ensure the develop-ability of MMJ’s molecules. The combined team of pharmaceutical development experts will apply collaborative, scalable and science-based approaches to proactively solve a wide range of formulation development challenges from dosing, bioavailability and stability of MMJ’s complex formulations. 

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Sharpe
Visit website